Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulati

[News]

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

More... (http://www.news-medical.net/news/20100805/Sanofi-aventis-receives-FDA-approval-for-new-Taxotere-Injection-Concentrate-formulation.aspx)